Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders
National Institutes of Health (NIH)
Up to $300,000 per year for a maximum of five years.
To support early-stage investigators proposing highly innovative studies in the genetics or epigenetics of substance use disorders.
Early-stage investigators, researchers in the field of addiction, and ultimately individuals affected by substance use disorders.
NIH funding, grant type.
Recurring, with applications due annually.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)
Applicants must be classified as Early Stage Investigators (ESI).
Must be based in the United States.
Applicants should demonstrate potential for high-impact research.
Independent research position at a domestic institution is required.
Innovative studies in genetics or epigenetics of substance use disorders.
Research that opens new areas of understanding in addiction.
Skills and knowledge necessary to carry out the proposed research.
Limited to $300,000 in direct costs each year.
Applications due by September 25 each year until 2025.
Must comply with NIH Grants Policy Statement.
Applications must follow the SF424 (R&R) Application Guide.